Study of MK-3475 Alone or in Combination With Copanlisib in Relapsed or Refractory NK and T-cell Non-Hodgkin Lymphoma

NCT02535247 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

17

Enrollment

OTHER

Sponsor class

Stopped Merck no longer providing drug for study

Conditions

Lymphoma, T-Cell, Peripheral

Interventions

DRUG: MK-3475
DRUG: Copanlisib

Sponsor

Fox Chase Cancer Center

Collaborators

[object Object]